Lupin Limited

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 12:30:38 18/05/2024 pm IST			5-day change	1st Jan Change
1,660 ^INR	0.00%		+3.11%	+25.46%

10:36am	Lupin Gets Six Observations from US FDA After Somerset Unit Inspection	MT
13/05	Lupin Relaunches Mirabegron ER Tablets in US	MT

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

December 22, 2022 at 07:31 pm IST

Lupin Limited announced that Ms. Christine Mundkur, Independent Director will be stepping down from the Board of Directors of the Company, effective January 1, 2023, to avoid any conflict of interest since she has recently joined the Board of Cardinal Health, USA as an Independent Director.

Latest news about Lupin Limited

Lupin Gets Six Observations from US FDA After Somerset Unit Inspection	02:06pm	MT
Lupin Relaunches Mirabegron ER Tablets in US	13/05	MT
Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	09/05	MT
Lupin Limited Announces Board Appointments	09/05	CI
Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold	08/05	MT
Transcript : Lupin Limited, Q4 2024 Earnings Call, May 07, 2024	07/05
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	07/05	MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	06/05	RE
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	06/05	CI
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06/05	CI
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat	30/04	CI
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	24/04	MT
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	22/04	RE
Lupin Launches Mirabegron Extended-Release Tablets in US	22/04	MT
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration	20/04	CI
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection	12/04	MT
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	10/04	MT
Lupin Launches Generic Drug for Inflammatory Lesions of Rosacea in US	09/04	MT
Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States	09/04	CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	03/04	MT
Lupin Names Chief Quality Officer	03/04	MT
Lupin Limited Announces Change in Management	03/04	CI
Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences	25/03	MT
Lupin Limited Receives an Order from the Additional Commissioner of State Tax, Central Division, Patna	21/03	CI
Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms	18/03	MT

Chart Lupin Limited

Duration

Period

More charts

Company Profile

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lupin Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,660 INR

Average target price

1,567 INR

Spread / Average Target

-5.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUPIN LIMITED	+25.46%	9.08B
ELI LILLY AND COMPANY	+34.39%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-2.75%	372B
MERCK & CO., INC.	+20.54%	332B
ABBVIE INC.	+6.73%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+9.02%	168B

Other Pharmaceuticals

Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

EPS Revisions